Natamycin: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Ophthalmic
Fungal keratitis

Adult: As 5% ophthalmic susp: Initially, instil 1 drop into the conjunctival sac of the affected eye(s) 1-2 hourly. Reduce dose to 1 drop 6-8 times daily after 3-4 days or gradually at 4- to 7-day intervals. Treatment duration: 14-21 days or until resolution of symptoms.

Ophthalmic
Fungal blepharitis, Fungal conjunctivitis

Adult: As 5% ophthalmic susp: Instil 1 drop into the conjunctival sac of the affected eye(s) 4-6 times daily.

What are the brands available for Natamycin in Indonesia?

Fukricin

Contraindications

Hypersensitivity.

Special Precautions

Pregnancy and lactation.

Adverse Reactions

Cardiac disorders: Chest pain.
Eye disorders: Visual disturbance, corneal opacity, eye discomfort, hyperaemia, periorbital oedema, eye pain, eye irritation, foreign body sensation of eye, lacrimation.
Immune system disorders: Hypersensitivity reaction.
Respiratory, thoracic and mediastinal disorders: Dyspnoea.

Patient Counseling Information

Avoid wearing contact lenses during therapy.

Monitoring Parameters

Reevaluate treatment if there is no improvement after 7-10 days of therapy.

Action

Description:
Mechanism of Action: Natamycin is a tetraene polyene antifungal antibiotic with predominant fungicidal activity. It binds to the sterol moiety of fungal cell membrane and alters the membrane permeability, thereby causing depletion of essential cellular contents.
Pharmacokinetics:
Distribution: Adheres into cornea; retained in conjunctival fornices.

Chemical Structure

Storage

Store between 2-24°C. Do not freeze. Protect from light and excessive heat.

MIMS Class

Eye Anti-Infectives & Antiseptics

ATC Classification

S01AA10 - natamycin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.

References

Anon. Natamycin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 10/10/2024.

Brayfield A, Cadart C (eds). Natamycin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/10/2024.

Natacyn Ophthalmic Suspension (Link Healthcare Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 10/10/2024.

Natacyn Suspension/Drops (Eyevance Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 10/10/2024.

Natamycin. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 10/10/2024.

Natamycin. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 10/10/2024.

Disclaimer: This information is independently developed by MIMS based on Natamycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com